Delivery Order 75N95023D00019-75N95023F00001
Award Date
9/25/23
Potential Completion Date
7/23/25
Potential Value
$1.8M
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Overland Park, KS 66212, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the National Institute on Drug Abuse (NIDA), a civilian agency, to Altasciences Clinical Kansas Inc., a for-profit contract research organization (CRO). The $1,340,461.88 firm fixed-price delivery order is for a clinical trial to assess the safety, tolerability, and pharmacokinetics of an investigational agent for substance use disorder (SUD) treatment. The contract is part of NIDA's $21 million indefinite delivery contract N01DA-23-8935, which supports...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $1,436,776 firm fixed price delivery order to Altasciences Clinical Kansas Inc. to conduct a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent from September 3, 2024 to March 2, 2026. This delivery order was issued against an existing $21 million single-award indefinite delivery contract with NIDA for pharmacokinetic and pharmacodynamic...
This is a $983,066 firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization, to conduct a bioequivalence study of lamotrigine extended release tablets. The delivery order was issued against an existing $21 million single-award indefinite delivery contract with the National Institute on Drug Abuse (NIDA) for pharmacokinetic and pharmacodynamic trials to develop medications for substance use...
This federal contract award was made by the Food and Drug Administration (FDA) to Altasciences Clinical Kansas Inc., a contract research organization specializing in early phase drug development services. The $1,293,840.24 firm fixed price definitive contract is for a project on the pharmacokinetics study of an opioid drug product following insufflation of milled drug products. The contract has an ultimate completion date of September 30, 2019 and was awarded on September 17, 2015. No...
The Food and Drug Administration (FDA) awarded a $2,370,057 firm fixed price definitive contract to Altasciences Clinical Kansas Inc., a contract research organization, for a dose-finding pilot study of kratom alkaloids to be conducted in Silver Spring, Maryland through September 2024. This award was not set aside under any small business programs. Altasciences has prior experience providing clinical pharmacology research services to federal agencies, including a $1.8 million firm fixed price...
The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a firm fixed-price purchase order valued at $22,500 to the University of Kansas Center for Research, Inc. This award is pursuant to a request for quote to develop a manufacturable tablet formulation of the compound NCGC72 for use in dog sarcoma clinical studies. The prime contractor will non-GMP manufacture 1,500 tablets total, with 1,000 tablets at 50mg dosage and 500 tablets at...
This $23,800.00 firm fixed-price purchase order was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian federal agency, to the University of Kansas Center for Research Inc. on September 12, 2024. The contract is for preliminary solid dosage form development strategy of an ALDH1A1 inhibitor drug candidate for NCATS' Extramural Research and Training Branch (ETB). This contract does not have a set-aside designation. The University of Kansas Center for Research...
This federal contract award, with an ID of 75N95019D00009|75N95023F00001, is for a Phase I Cocaine Drug Interaction Study to be conducted by the National Institute on Drug Abuse (NIDA) Pharmacokinetic Analysis Resource Center. The $269,663.00 Delivery Order contract, which runs from August 10, 2023 to February 9, 2025, has been awarded to Technical Resources International, Inc. (TRI), a minority-owned, woman-owned, and Hispanic American-owned small business based in Bethesda, Maryland. The...
This is a Delivery Order issued under the Scientific, Operations, and Administrative Resources to the National Institutes of Health (SOAR) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The prime contractor is Medical Science & Computing, LLC, a for-profit limited liability company that provides scientific research and information technology services to federal agencies, particularly the Department of Health and Human Services' National Institutes of Health (NIH) and its...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Southern Research Institute, a non-profit organization. The $1,593,565.26 contract is under the Pharmacology and Toxicology for Neurotherapeutics Program (PTNP) indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The contract is for the 28-day oral toxicity study in monkeys with a 33-day recovery period. Southern Research Institute has subcontracted a...